Provided by Tiger Fintech (Singapore) Pte. Ltd.

Repare Therapeutics Inc.

1.58
+0.02001.28%
Post-market: 1.590.0100+0.63%16:18 EDT
Volume:219.89K
Turnover:349.74K
Market Cap:67.77M
PE:-0.52
High:1.62
Open:1.57
Low:1.56
Close:1.56
Loading ...

Repare Therapeutics Signs Licensing Deal with Debiopharm

TIPRANKS
·
17 Jul

TD Cowen Reaffirms Their Buy Rating on Repare Therapeutics (RPTX)

TIPRANKS
·
16 Jul

LifeSci Capital Sticks to Their Hold Rating for Repare Therapeutics (RPTX)

TIPRANKS
·
16 Jul

BUZZ-Repare Therapeutics jumps on cancer drug licensing deal

Reuters
·
16 Jul

Repare Therapeutics Announces Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib Development and Collaboration

Reuters
·
16 Jul

Repare Therapeutics Inc - to Receive $10 Mln Upfront, $257 Mln in Milestones

THOMSON REUTERS
·
16 Jul

Repare Therapeutics Inc - Debiopharm to Sponsor Mythic Study and Develop Lunresertib

THOMSON REUTERS
·
16 Jul

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement With Debiopharm for Lunresertib

THOMSON REUTERS
·
16 Jul

Repare Therapeutics Inc. Updates Severance Benefits for Executive Michael Zinda

Reuters
·
21 Jun

Repare Therapeutics Inc. Conducted Annual Shareholder Meeting

Reuters
·
18 Jun

Repare Therapeutics Strengthens Leadership with New Executive Appointment

TIPRANKS
·
03 Jun

Repare Therapeutics Reports $124.2M in Cash and Securities, Announces Strategic Partnership and Pipeline Advancements in Q1 2025 Results

Reuters
·
14 May

Repare Therapeutics Inc: Exploring Strategic Alternatives to Advance Clinical Stage Pipeline and Maximize Shareholder Value

THOMSON REUTERS
·
14 May

Repare Therapeutics Inc: Cash, Cash Equivalents, and Marketable Securities Are Sufficient to Fund Its Current Operational Plans Through 2027

THOMSON REUTERS
·
14 May

LifeSci Capital Keeps Their Hold Rating on Repare Therapeutics (RPTX)

TIPRANKS
·
02 May

Repare Therapeutics Inc. Enters Partnership with DCx Biotherapeutics to Out-License Discovery Platforms

Reuters
·
01 May

DCx Biotherapeutics Partners with Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Reuters
·
01 May

Repare Therapeutics Announces Out-Licensing of Its Discovery Platforms to Dcx Biotherapeutics

THOMSON REUTERS
·
01 May

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Business Wire
·
01 May

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Business Wire
·
26 Apr